1. Buyssee DJ. Insomnia. JAMA. 2013;309(7):706.
2. Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders: rationale for development and current status. CNS Drugs. 2013;27(2):83–90.
3. US Food and Drug Administration. FDA approves new type of sleep drug, Belsomra [media release]. 13 August 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm .
4. Merck & Co. BELSOMRA® (suvorexant) US prescribing information. 2014. http://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf . Accessed 18 Aug 2014.
5. Merck & Co. Merck receives Complete Response Letter for suvorexant, Merck’s investigational medicine for insomnia [media release]. 1 July 2013. http://www.merck.com .